東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Synergistic inhibition of cyclooxyge...

Crowe, Molly S.

FindBook

Google Book

Amazon

博客來

Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain./
作者:	Crowe, Molly S.
面頁冊數:	35 p.
附註:	Source: Masters Abstracts International, Volume: 52-04.
Contained By:	Masters Abstracts International52-04(E).
標題:	Psychology, Behavioral. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1549738
ISBN:	9781303625640

Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain.
Crowe, Molly S.

Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain. - 35 p.

Source: Masters Abstracts International, Volume: 52-04.

Thesis (M.S.)--West Virginia University, 2014.

Neuropathic pain is caused by altered nerve function that often presents as allodynia, which is the painful perception of typically non-noxious stimuli. Neuropathic pain is commonly treated with GABA analogues, steroids, or non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs inhibit one or more cyclooxygenase (COX) enzymes and are effective, commonly used analgesics that have relatively fewer side effects than other treatments. However, chronic cyclooxygenase inhibition also causes gastrointestinal inflammation and increased risk of cardiac events. Like NSAIDs, cannabinoids have analgesic and anti-inflammatory properties and reduce neuropathic pain in preclinical models. The present study investigated the analgesic effects of inhibiting both monoacylglycerol lipase (MAGL) and cyclooxygenase enzymes. Mice subjected to the chronic constriction injury (CCI) model of neuropathic pain were administered either the MAGL inhibitor, JZL184 (1-40 mg/kg, i.p.) or the nonselective COX inhibitor diclofenac sodium (1-100 mg/kg, i.p.) and tested for mechanical and cold allodynia. Then, both drugs were coadministered at various doses in ratios of 1:3, 1:1, and 3:1 parts of either compound. Isobolographic analyses revealed that combining low doses of JZL184 and diclofenac synergistically attenuated mechanical allodynia and additively reduced cold allodynia. These data support dual COX/MAGL inhibition as a promising therapeutic approach for neuropathic pain.

ISBN: 9781303625640Subjects--Topical Terms:

1017677
Psychology, Behavioral.

Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain.
LDR:02327nam a2200277 4500 001 1967229
005 20141112080243.5
008 150210s2014 ||||||||||||||||| ||eng d
020 $a 9781303625640
035 $a (MiAaPQ)AAI1549738
035 $a AAI1549738
040 $a MiAaPQ $c MiAaPQ
100 1 $a Crowe, Molly S. $3 2104180
245 1 0 $a Synergistic inhibition of cyclooxygenases and monoacylglycerol lipase in neuropathic pain.
300 $a 35 p.
500 $a Source: Masters Abstracts International, Volume: 52-04.
500 $a Adviser: Steven G. Kinsey.
502 $a Thesis (M.S.)--West Virginia University, 2014.
520 $a Neuropathic pain is caused by altered nerve function that often presents as allodynia, which is the painful perception of typically non-noxious stimuli. Neuropathic pain is commonly treated with GABA analogues, steroids, or non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs inhibit one or more cyclooxygenase (COX) enzymes and are effective, commonly used analgesics that have relatively fewer side effects than other treatments. However, chronic cyclooxygenase inhibition also causes gastrointestinal inflammation and increased risk of cardiac events. Like NSAIDs, cannabinoids have analgesic and anti-inflammatory properties and reduce neuropathic pain in preclinical models. The present study investigated the analgesic effects of inhibiting both monoacylglycerol lipase (MAGL) and cyclooxygenase enzymes. Mice subjected to the chronic constriction injury (CCI) model of neuropathic pain were administered either the MAGL inhibitor, JZL184 (1-40 mg/kg, i.p.) or the nonselective COX inhibitor diclofenac sodium (1-100 mg/kg, i.p.) and tested for mechanical and cold allodynia. Then, both drugs were coadministered at various doses in ratios of 1:3, 1:1, and 3:1 parts of either compound. Isobolographic analyses revealed that combining low doses of JZL184 and diclofenac synergistically attenuated mechanical allodynia and additively reduced cold allodynia. These data support dual COX/MAGL inhibition as a promising therapeutic approach for neuropathic pain.
590 $a School code: 0256.
650 4 $a Psychology, Behavioral. $3 1017677
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0384
690 $a 0419
710 2 $a West Virginia University. $b Eberly College of Arts and Sciences. $3 2104181
773 0 $t Masters Abstracts International $g 52-04(E).
790 $a 0256
791 $a M.S.
792 $a 2014
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1549738